LPCN insider trading
NasdaqCM HealthcareLipocine Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Lipocine Inc.
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 to treat postpartum depression; LPCN 2101, a NAS candidate for women with epilepsy; and LPCN 2203, an oral candidate for management of essential tremor. It also develops LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of metabolic dysfunction-associated steatohepatitis; LPCN 2401 to improve body composition in obesity management; and LPCN 1107, an oral hydroxy progesterone caproate product indicated for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
Company website: www.lipocine.com
LPCN insider activity at a glance
FilingIQ has scored 95 insider transactions for LPCN since May 15, 2015. The most recent filing in our index is dated Apr 7, 2026.
Across the full history, 28 open-market purchases
and 14 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on LPCN insider trades is 64.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest LPCN Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading LPCN
Frequently asked
- How many insider trades does FilingIQ track for LPCN?
- FilingIQ tracks 95 Form 4 insider transactions for LPCN (Lipocine Inc.), covering filings from May 15, 2015 onwards. 4 of those were filed in the last 90 days.
- Are LPCN insiders net buyers or net sellers?
- Across the full Form 4 history for LPCN, 28 transactions (29%) were open-market purchases and 14 (15%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does LPCN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is LPCN in?
- Lipocine Inc. (LPCN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $49.91M.
Methodology & sources
Every LPCN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.